As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Opus Genetics Inc. The largest reported stake is Perceptive Advisors LLC's, at 9.99%. 17 filings are on record since August 11, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Opus Genetics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 4,961,536 · Shared voting: 0 · Sole dispositive: 5,044,847 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 9,233,710 · Sole dispositive: 0 · Shared dispositive: 9,233,710 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Caligan Partners LP · Sole voting: 0 · Shared voting: 6,077,084 · Sole dispositive: 0 · Shared dispositive: 6,077,084 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 5,480,210 · Shared voting: 0 · Sole dispositive: 5,480,210 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Foundation Fighting Blindness Retinal Degeneration Fund · Percent: 4.66% · SCHEDULE 13D/A
Opus Genetics Inc has 17 Schedule 13D or 13G filings on record since 2025-08-11. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.99% | 9,233,710 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Adage Capital Management, L.P. | 8.47% | 6,029,775 | SCHEDULE 13G, 2026-05-13 | 2026-03-31 |
| Caligan Partners LP | 7.3% | 6,077,084 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Balyasny Asset Management L.P. | 6.64% | 5,480,210 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Nantahala Capital Management, LLC | 6.51% | 4,839,225 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 6.1% | 5,044,847 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Foundation Fighting Blindness Retinal Degeneration Fund | 4.66% | 3,792,171 | SCHEDULE 13D/A, 2026-05-20 | 2026-05-18 |
| 4.53% | 3,683,429 | SCHEDULE 13G/A, 2026-05-13 | 2026-05-12 |
Holding shares or following this stake? See who's behind Opus Genetics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Opus Genetics Inc and the records around it.
Opus Genetics Inc elsewhere on the record
Companies that share a holder
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Balyasny Asset Management L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Watch Opus Genetics Inc
Get an email when Opus Genetics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Opus Genetics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Opus Genetics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Opus Genetics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 0 | 9,233,710 | 0 | 9,233,710 | SCHEDULE 13G/A, 2026-08-14 |
| Joseph Edelman | 0 | 9,233,710 | 0 | 9,233,710 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 9,233,710 | 0 | 9,233,710 | SCHEDULE 13G/A, 2026-08-14 |
| Caligan Partners LP | 0 | 6,077,084 | 0 | 6,077,084 | SCHEDULE 13G/A, 2026-08-14 |
| Johnson David Edward | 0 | 6,077,084 | 0 | 6,077,084 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management L.P. | 5,480,210 | 0 | 5,480,210 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Bam Gp LLC | 5,480,210 | 0 | 5,480,210 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 5,480,210 | 0 | 5,480,210 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dames GP LLC | 5,480,210 | 0 | 5,480,210 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dmitry Balyasny | 5,480,210 | 0 | 5,480,210 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 4,961,536 | 0 | 5,044,847 | 0 | SCHEDULE 13G, 2026-10-27 |
The latest filing identifies Opus Genetics Inc by CUSIP 67577R102 and gives its principal executive office as 8 Davis Drive, Durham, NC 27713 (SCHEDULE 13G, 2026-10-27).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 6.64% of the Shares, based on 82,565,835 Shares outstanding as of May 31, 2026, as reported in the Issuer's Form S-3 filed with the Securities and Exchange Commission on June 5, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-11 | Bios Equity Partners Iii, LP | 6.2% | SCHEDULE 13G |
| 2025-08-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-12-11 | Foundation Fighting Blindness Retinal Degeneration Fund | 8% | SCHEDULE 13D/A |
| 2026-02-13 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Balyasny Asset Management L.P. | 7.41% | SCHEDULE 13G |
| 2026-02-17 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 8.47% | SCHEDULE 13G |
| 2026-05-13 | Aaron G.L. Fletcher | 4.53% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Management, LLC | 6.51% | SCHEDULE 13G/A |
| 2026-05-15 | Balyasny Asset Management L.P. | 7.18% | SCHEDULE 13G/A |
| 2026-05-15 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | Caligan Partners LP | 8.5% | SCHEDULE 13G |
| 2026-05-20 | Foundation Fighting Blindness Retinal Degeneration Fund | 4.66% | SCHEDULE 13D/A |
| 2026-08-14 | Balyasny Asset Management L.P. | 6.64% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Caligan Partners LP | 7.3% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 6.1% | SCHEDULE 13G |
Questions about who owns Opus Genetics Inc
Who owns Opus Genetics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Opus Genetics Inc: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Adage Capital Management, L.P. (8.47%, Schedule 13G, filed 2026-05-13), Caligan Partners LP (7.3%, Schedule 13G/A, filed 2026-08-14), Balyasny Asset Management L.P. (6.64%, Schedule 13G/A, filed 2026-08-14) and Nantahala Capital Management, LLC (6.51%, Schedule 13G/A, filed 2026-05-15); 1 more is listed above.
Who are the largest shareholders of Opus Genetics Inc?
By the share each holder's latest filing reports, the largest holders of Opus Genetics Inc on this page are Perceptive Advisors LLC (9.99%), Adage Capital Management, L.P. (8.47%) and Caligan Partners LP (7.3%).
When did Perceptive Advisors LLC buy into Opus Genetics Inc?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Opus Genetics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 21, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Opus Genetics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.